Last update July 14, 2023


Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

Rotigotine is a non-selective non-ergot dopaminergic D2 agonist used for the treatment of Parkinson's disease and restless legs syndrome. It has actions similar to those of bromocriptine. Administration in the form of transdermal patches every 24 hours.

At the date of the last update we did not find any published data on its excretion in breast milk.

Its pharmacokinetic data (very large volume of distribution and high percentage of binding to plasma proteins) make it unlikely to pass into breast milk in clinically significant quantities.

Being a dopamine agonist, it is very likely to decrease prolactin secretion. Milk production, once lactation is established, is not so much dependent on prolactin as on the frequency of breastfeeding or milk expression. (Messinis 1985)

If it is administered during lactation, it is advisable not to take it during the first postpartum month and to monitor milk production.


  • Gabapentin (Safe substance and/or breastfeeding is the best option.)
  • Pregabalin (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Ротиготин is Rotigotine in Cyrillic.

Is written in other languages:


Ротиготин belongs to this group or family:


Main tradenames from several countries containing Ротиготин in its composition:


Variable Value Unit
Molecular weight 316 daltons
Protein Binding 90 %
VD 84 l/Kg
pKa 10.03 -
Tmax 15 - 24 hours
5 - 7 hours


  1. UCB. Rotigotine. Drug Summary. 2017 Full text (in our servers)
  2. EMA. Rotigotina. Ficha técnica. 2016 Full text (in our servers)
  3. Messinis IE, Souvatzoglou A, Fais N, Lolis D. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. J Endocrinol Invest. 1985 Apr;8(2):143-6. Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM